Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada.

"Conflicts of interest There are no conflicts of interests."

"C.T.C. is supported by a Fonds de recherche du Québec-Santé (FRQS) Junior 2 career award. A.B. holds a Canada Research Chair Tier 2 Canada Research Chair (CRC) in sexually transmitted infection (STI) Prevention. M.A.L. holds a CRC, Tier 2, in human immunovirology. M.A.J. holds a CRC, Tier 2, in human immunovirology. S.W. is supported by a Research Chair in HIV Clinical Care and Aging from the Ontario HIV Treatment Network. D.T. is supported by a Tier 2 CRC in HIV Prevention and STI Research. M.A.B. holds a Canada Research Chair, Tier 2, in viral pathogenesis and immunity. Z.L.B. holds a Scholar Award from the Michael Smith Foundation for Health Research. B.L. is supported by a career award LE 250 from the Quebec's Ministry of Health for researchers in Family Medicine, FRQS Junior 2 career award and holds a Canadian Institutes for Health Research Strategy for Patient Oriented Research (SPOR) Mentorship Chair in Innovative Clinical Trials. J.P.R. holds a Lowenstein Chair in Hematology. Y.G. is supported by a Charles Best and Frederick Bandting (CGS-Doctoral award) from CIHR (476885). Funding This project was supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force (grant number: 2122-HQ-000075) and the CTN (grant number: N/A). Production of COVID-19 reagents was financially supported by NRC's Pandemic Response Challenge Program."

"Trial registration: clinicaltrials.gov NCT04894448."